Open AccessSurvival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies
Author(s) -
Yun Seon Song,
Andrew Tieniber,
Phyllis A. Gimotty,
Tara C. Mitchell,
Ravi K. Amaravadi,
Lynn M. Schuchter,
Douglas L. Fraker,
Giorgos C. Karakousis
Publication year - 2019
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-019-07599-y
Subject(s) - medicine , melanoma , context (archaeology) , stage (stratigraphy) , hazard ratio , bonferroni correction , surgical oncology , clinical trial , population , cancer , retrospective cohort study , log rank test , proportional hazards model , oncology , confidence interval , paleontology , statistics , mathematics , environmental health , cancer research , biology
Immune checkpoint and BRAF-targeted inhibitors have demonstrated significant survival benefits for advanced melanoma patients within the context of clinical trials. We sought to determine their impact on overall survival (OS) at a population level in order to better understand the current landscape for patients diagnosed with clinical stage III melanoma.